Ehab L. Atallah, MD

Articles by Ehab L. Atallah, MD

Clarifying the Use of Ruxolitinib in Patients With Myelofibrosis

ByMarina Kremyanskaya, MD,Ehab L. Atallah, MD,Ronald Hoffman, MD,John O. Mascarenhas, MD

July 15th 2013

In this article, we provide updated data on ruxolitinib therapy for patients with myelofibrosis and offer expert opinion on the appropriate use of this agent in the community practice.

Latest Updated Articles

Clarifying the Use of Ruxolitinib in Patients With Myelofibrosis
July 15th 2013

Trending on CancerNetwork

Durvalumab Plus BCG Earns FDA Approval For High-Risk NMIBC

FDA Approves Pivekimab Sunirine in Rare Hematologic Malignancy

Toripalimab Regimen Improves EFS, MPR Rate in Stage II/III NSCLC Trial

This Week in Breast Cancer: Camizestrant Delay, Bria-IMT Data, Recurrence Test

87 Gedatolisib, a Multitarget PI3K/AKT/mTOR (PAM) Inhibitor, Plus Fulvestrant With or Without Palbociclib for Second-Line (2L) Treatment of Patients With HR+/HER2–/PIK3CA-Wild Type (WT) Advanced Breast Cancer (ABC): Topline Results From VIKTORIA-1